Compare
Lexaria Bioscience Corp. vs BioXcel Therapeutics, Inc. vs Hyperion Defi, Inc. vs Onconetix, Inc.
| Latest fiscal year | Lexaria Bioscience Corp. LEXX | BioXcel Therapeutics, Inc. BTAIQ | Hyperion Defi, Inc. HYPD | Onconetix, Inc. ONCO |
|---|---|---|---|---|
| Year ended | 2025-08-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $705.9K | $642.0K | $813.5K | $815.4K |
| Revenue growth (YoY) | +52.0% | -71.7% | n/m | -67.7% |
| Gross margin | 99.6% | 74.5% (computed) | 62.7% | 77.6% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$11.90M | -$69.90M | -$45.31M | -$14.03M |
| EPS (Diluted) | -$0.66 | -$5.73 | -$9.40 | -$16.56 |
| Operating cash flow | -$10.45M | -$57.62M | -$14.77M | -$9.68M |
| Free cash flow | -$10.48M | -$57.62M | n/a | n/a |
| Cash & equivalents | n/a | $28.41M | $6.44M | n/a |
| Total assets | $4.18M | $44.92M | $51.76M | $24.93M |
| Total liabilities | $1.57M | $140.38M | $10.70M | $9.16M |
| Shareholders' equity | $2.99M | -$95.46M | $41.06M | $15.76M |
| Return on year-end equity | -398.1% | n/a | -110.4% | -89.0% |
| Shares outstanding | 19.56M | 22.33M | 8.68M | 1.56M |
Revenue, most recent five fiscal years
| Fiscal year | Lexaria Bioscience Corp. | BioXcel Therapeutics, Inc. | Hyperion Defi, Inc. | Onconetix, Inc. |
|---|---|---|---|---|
| Latest | $705.9K Ended 2025-08-31 | $642.0K Ended 2025-12-31 | $813.5K Ended 2025-12-31 | $815.4K Ended 2025-12-31 |
| 1 year earlier | $464.3K Ended 2024-08-31 | $2.27M Ended 2024-12-31 | $57.3K Ended 2024-12-31 | $2.52M Ended 2024-12-31 |
| 2 years earlier | $226.2K Ended 2023-08-31 | $1.38M Ended 2023-12-31 | $3.8K Ended 2023-12-31 | $58.5K Ended 2023-12-31 |
| 3 years earlier | $255.4K Ended 2022-08-31 | $375.0K Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | $722.7K Ended 2021-08-31 | n/a | $14.00M Ended 2021-12-31 | n/a |